ABSTRACT
Immunoglobulin idiotype antigen vaccines 1540 KLH-conjugated idiotype protein vaccines 1541 Production of human idiotype vaccines and phase I/II 1541
clinical trials in follicular lymphoma Idiotype vaccine following rituximab therapy in mantle 1542
cell lymphoma Phase III study design 1542
Other lymphoma vaccines 1543 Second-generation lymphoma idiotype vaccines 1543 Liposomal-formulated idiotype vaccine 1544 Chemokine-idiotype single-chain fusion DNA vaccines 1544 Summary and future directions 1547 Key points 1548 References 1548
The development of therapeutic vaccines against human malignancies has been a long-sought goal. Many efforts toward this end have been frustrated by the lack of identified, tumor-specific antigens that would allow tumor cells to be distinguished from normal cells. Conceptually, such an antigen could be used as an immunogen to activate host antitumor immunity.
